Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections
Author:
- 5 June 2014
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 370 (23) , 2238-2239
Abstract
Skin and skin-structure infections are estimated to cause more than 15 million infections1 and 870,000 hospital admissions2 annually in the United States. Rates of these infections are substantially higher than they were 10 to 20 years ago, owing in part to the emergence of methicillin-resistant Staphylococcus aureus in the community.3 Two articles in this issue of the Journal report the results of phase 3, randomized, double-blind clinical trials (one of dalbavancin4 and the other of oritavancin5) for the treatment of acute bacterial skin and skin-structure infections. Although neither antibiotic agent is new (both date to the 1990s), they could . . .Keywords
This publication has 7 references indexed in Scilit:
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionNew England Journal of Medicine, 2014
- Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin InfectionsNew England Journal of Medicine, 2014
- Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based studyBMC Infectious Diseases, 2013
- Epidemics of Community-Associated Methicillin-Resistant Staphylococcus aureus in the United States: A Meta-AnalysisPLOS ONE, 2013
- In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in HumansClinical Infectious Diseases, 2012
- New LipoglycopeptidesDrugs, 2010
- Trends in US Hospital Admissions for Skin and Soft Tissue InfectionsEmerging Infectious Diseases, 2009